Join to view full profile
160 E 34th StNew York, NY 10016
Phone+1 212-731-5431
Fax+1 732-212-0713
Dr. Mehnert is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Janice Mehnert is an oncology specialist based in New York, NY, affiliated with NYU Langone Health and NYU Langone Hospitals since 2020, where she serves as a professor and associate director of clinical research. She is a specialist in cutaneous oncology with a focus on melanoma and Merkel cell carcinoma. Her educational background includes a fellowship in Hematology and Medical Oncology at Yale-New Haven Medical Center and a residency in Internal Medicine at Icahn School of Medicine at Mount Sinai. She completed her medical degree at Rutgers Robert Wood Johnson Medical School. She has authored several publications, with her work on melanoma and immune-related adverse events being notably cited. Her research interests involve clinical trials focusing on advanced melanoma and various innovative cancer treatments.
Education & Training
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2001 - 2004
Rutgers Robert Wood Johnson Medical SchoolClass of 2001
Certifications & Licensure
NY State Medical License 2020 - 2027
NJ State Medical License 2007 - 2021
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy Start of enrollment: 2010 Feb 19
- Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery
- Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma Start of enrollment: 2011 Feb 18
Publications & Presentations
PubMed
- 1 citationsSystemic Therapies for the Treatment of Cutaneous Malignancies in Solid Organ Transplant Recipients.Akshay Pulavarty, Derek Maas, Archie Spindler, Alissa Kalyan, Nayoung Lee
Dermatologic Surgery. 2026-10-01 - 4 citationsIntismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study.Adnan Khattak, Matteo S Carlino, Tarek Meniawy, George Ansstas, Matthew H Taylor
Journal of Clinical Oncology. 2026-09-10 - Focal Small Bowel FDG Uptake in Cancer Patients Undergoing PET/CT: Prevalence and Etiology.Charlotte Charbel, Sungmin Woo, Anton S Becker, Adam Bruzzese, Doris Leithner
Clinical Nuclear Medicine. 2026-08-01
Journal Articles
- Prognostic Gene Expression Profiling in Cutaneous MelanomaDouglas Grossman, Sancy A Leachman, Larissa Korde, Elizabeth I Buchbinder, Emily Y Chu, Julia A Curtis, Laura K Ferris, Kenneth F Grossmann, Siwen Hu-Lieskovan, Kari L..., JAMA Dermatology
- Autophagy Maintains Tumour Growth Through Circulating ArginineJanice M Mehnert, Marcus W Bosenberg, Nature
- The Challenge for Development of Valuable Immuno-Oncology BiomarkersArta M Monjazeb, Janice M Mehnert, Lyndsay N Harris, Clinical Cancer Research
Authored Content
- Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
- Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
- Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
Press Mentions
ASCO 2026 News: Personalized MRNA-Based Melanoma Vaccine Plus Immunotherapy Slashes Risk of Recurrence and DeathJune 1st, 2026- Immunotherapy After Surgery Shows Potential in Preventing the Spread of Aggressive Skin CancerOctober 21st, 2025
- Post-Surgery Immunotherapy Shows Promise in Halting Spread of Aggressive Skin CancerOctober 20th, 2025
Grant Support
- K12 Training for Clinical and Translational Oncology ResearchersNEW YORK UNIVERSITY SCHOOL OF MEDICINE2023–2028
- “Promoting a Culture Of Innovation, Mentorship, and Clinical Investigation in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.DNEW YORK UNIVERSITY SCHOOL OF MEDICINE2023–2028
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
